FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308903989> ?p ?o ?g. }

• W4308903989 endingPage "101122" @default.
• W4308903989 startingPage "101122" @default.
• W4308903989 abstract "Local tumor progression is a cause of significant morbidity and mortality in patients with pancreatic ductal adenocarcinoma (PDAC) with surgically unresectable disease. Novel and effective approaches to accomplish durable local control are urgently needed. We tested whether CPI-613 (devimistat), a first-in-class investigational small molecule inhibitor of mitochondrial metabolism, was capable of altering cancer cell energy metabolism and sensitizing PDAC cells to radiation therapy (RT).The effect of a combined treatment of RT with CPI-613 on the viability of, clonogenic potential of, and cell death induction in PDAC cells (MiaPaCa-2 and Panc-1) was determined using a trypan blue dye exclusion assay, a colony formation assay, and a 7-amino-actinomycin D assay, respectively. The synergistic effects of CPI-613-RT and chemotherapeutic agents (gemcitabine or 5-fluorouracil) were measured in MiaPaCa-2 cells using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and spheroid formation assay. Changes in energy metabolism were determined by profiling metabolites treated with either RT, CPI-613, or both using liquid chromatography-mass spectrometry.This study demonstrates that a combination of single-fraction RT (2 and 10 Gy) with CPI-613 significantly inhibits PDAC cell growth compared with RT alone. Molecular analysis revealed inhibition of α-ketoglutarate dehydrogenase at the protein level. In addition, we demonstrate enhanced cell death of PDAC cells when treated with RT-CPI-613 combination. Targeted metabolomic analysis on PDAC cells post-CPI-613-RT treatment revealed alterations in key mitochondrial metabolites, with broader target engagement by the combination treatment, indicating the sensitization of CPI-613-treated PDAC cells to RT. Furthermore, a combination treatment of CPI-613 with either gemcitabine or 5-fluorouracil in the presence of 2 Gy RT synergistically inhibits PDAC cell proliferation.Our results support a novel combination of CPI-613-RT that warrants further preclinical and early-phase clinical investigations. A phase 1 trial designed to identify the maximum tolerated dose of CPI-613 in combination with chemo-RT in patients with PDAC was recently initiated (NCT05325281)." @default.
• W4308903989 created "2022-11-19" @default.
• W4308903989 creator A5004268517 @default.
• W4308903989 creator A5006174923 @default.
• W4308903989 creator A5011817630 @default.
• W4308903989 creator A5013768762 @default.
• W4308903989 creator A5016599560 @default.
• W4308903989 creator A5016748416 @default.
• W4308903989 creator A5026049304 @default.
• W4308903989 creator A5037090507 @default.
• W4308903989 creator A5038465132 @default.
• W4308903989 creator A5041591287 @default.
• W4308903989 creator A5043733070 @default.
• W4308903989 creator A5044781652 @default.
• W4308903989 date "2023-01-01" @default.
• W4308903989 modified "2023-10-11" @default.
• W4308903989 title "Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy" @default.
• W4308903989 cites W1563283949 @default.
• W4308903989 cites W1983925309 @default.
• W4308903989 cites W2089756467 @default.
• W4308903989 cites W2118797060 @default.
• W4308903989 cites W2196287118 @default.
• W4308903989 cites W2346921980 @default.
• W4308903989 cites W2612422316 @default.
• W4308903989 cites W2808370854 @default.
• W4308903989 cites W2944888496 @default.
• W4308903989 cites W2972906233 @default.
• W4308903989 cites W3009237783 @default.
• W4308903989 cites W3011079318 @default.
• W4308903989 cites W3044632739 @default.
• W4308903989 cites W3135350757 @default.
• W4308903989 cites W3146983201 @default.
• W4308903989 cites W4206841660 @default.
• W4308903989 doi "https://doi.org/10.1016/j.adro.2022.101122" @default.
• W4308903989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36479231" @default.
• W4308903989 hasPublicationYear "2023" @default.
• W4308903989 type Work @default.
• W4308903989 citedByCount "1" @default.
• W4308903989 countsByYear W43089039892023 @default.
• W4308903989 crossrefType "journal-article" @default.
• W4308903989 hasAuthorship W4308903989A5004268517 @default.
• W4308903989 hasAuthorship W4308903989A5006174923 @default.
• W4308903989 hasAuthorship W4308903989A5011817630 @default.
• W4308903989 hasAuthorship W4308903989A5013768762 @default.
• W4308903989 hasAuthorship W4308903989A5016599560 @default.
• W4308903989 hasAuthorship W4308903989A5016748416 @default.
• W4308903989 hasAuthorship W4308903989A5026049304 @default.
• W4308903989 hasAuthorship W4308903989A5037090507 @default.
• W4308903989 hasAuthorship W4308903989A5038465132 @default.
• W4308903989 hasAuthorship W4308903989A5041591287 @default.
• W4308903989 hasAuthorship W4308903989A5043733070 @default.
• W4308903989 hasAuthorship W4308903989A5044781652 @default.
• W4308903989 hasBestOaLocation W43089039891 @default.
• W4308903989 hasConcept C109156525 @default.
• W4308903989 hasConcept C117262875 @default.
• W4308903989 hasConcept C121608353 @default.
• W4308903989 hasConcept C126322002 @default.
• W4308903989 hasConcept C1491633281 @default.
• W4308903989 hasConcept C185592680 @default.
• W4308903989 hasConcept C190283241 @default.
• W4308903989 hasConcept C2780070996 @default.
• W4308903989 hasConcept C2780210213 @default.
• W4308903989 hasConcept C2780258809 @default.
• W4308903989 hasConcept C31573885 @default.
• W4308903989 hasConcept C502942594 @default.
• W4308903989 hasConcept C55493867 @default.
• W4308903989 hasConcept C62231903 @default.
• W4308903989 hasConcept C71924100 @default.
• W4308903989 hasConcept C96232424 @default.
• W4308903989 hasConceptScore W4308903989C109156525 @default.
• W4308903989 hasConceptScore W4308903989C117262875 @default.
• W4308903989 hasConceptScore W4308903989C121608353 @default.
• W4308903989 hasConceptScore W4308903989C126322002 @default.
• W4308903989 hasConceptScore W4308903989C1491633281 @default.
• W4308903989 hasConceptScore W4308903989C185592680 @default.
• W4308903989 hasConceptScore W4308903989C190283241 @default.
• W4308903989 hasConceptScore W4308903989C2780070996 @default.
• W4308903989 hasConceptScore W4308903989C2780210213 @default.
• W4308903989 hasConceptScore W4308903989C2780258809 @default.
• W4308903989 hasConceptScore W4308903989C31573885 @default.
• W4308903989 hasConceptScore W4308903989C502942594 @default.
• W4308903989 hasConceptScore W4308903989C55493867 @default.
• W4308903989 hasConceptScore W4308903989C62231903 @default.
• W4308903989 hasConceptScore W4308903989C71924100 @default.
• W4308903989 hasConceptScore W4308903989C96232424 @default.
• W4308903989 hasFunder F4320307770 @default.
• W4308903989 hasFunder F4320332161 @default.
• W4308903989 hasIssue "1" @default.
• W4308903989 hasLocation W43089039891 @default.
• W4308903989 hasLocation W43089039892 @default.
• W4308903989 hasLocation W43089039893 @default.
• W4308903989 hasLocation W43089039894 @default.
• W4308903989 hasOpenAccess W4308903989 @default.
• W4308903989 hasPrimaryLocation W43089039891 @default.
• W4308903989 hasRelatedWork W1965851372 @default.
• W4308903989 hasRelatedWork W2094153719 @default.
• W4308903989 hasRelatedWork W2115579238 @default.
• W4308903989 hasRelatedWork W2126322332 @default.

• next